Introduction to the specifications and packaging contents of Iheli version of Inavolisib

Itovebi® (generic name: Inavolisib, trade name: Inavolisib) is a third-generation highly selective PI3Kα inhibitor developed by Roche. It has obtained national drug approval in China in 2025. The regulatory authority (NMPA) approved the marketing, and the indications are adult patients with hormone receptor-positive, HER2-negative, and PIK3CA mutated locally advanced or metastatic breast cancer. This drug is used in combination with palbociclib (palbociclib) and fulvestrant (fulvestrant) and is suitable for patients who are resistant to endocrine therapy.

The specification of Ihelai is 10 mg. It is packaged in bottles. Each bottle contains 30 tablets and is packed in aluminum-plastic blister. Each medicine is a film-coated tablet, white or off-white, and marked with "RG6114" for easy identification by patients. This drug is an oral dosage form, and patients can take it at the recommended dose under the guidance of a doctor.

In the Chinese market, Ihelai has not yet been included in the national medical insurance directory, and patients need to purchase it at their own expense. Specific pricing information may vary by region and sales channel, and patients are advised to consult their local hospital pharmacy or drug supplier for the latest pricing information. In addition, when using this drug, patients should follow the doctor's instructions and undergo relevant examinations regularly to ensure the safety and effectiveness of the treatment.

It should be noted that Ihelai may cause some adverse reactions, such as neutropenia, anemia, hyperglycemia, thrombocytopenia, lymphopenia, stomatitis, diarrhea, hypocalcemia, fatigue, hypokalemia, elevated creatinine, elevated transaminases, nausea, hyponatremia, hypomagnesemia, rash, loss of appetite, COVID-19 infection and headache. Patients should pay close attention to their own conditions during use and seek medical advice promptly if symptoms of discomfort occur. In addition, pregnant and lactating women should avoid using this drug and should consult a professional doctor for specific medication recommendations.

Reference materials:https://www.drugs.com/